Scarica l'app Stockscreener
0.882
0.02%
0.0002
Dopo l'orario di chiusura:
.91
0.028
+3.17%
Precedente Chiudi:
$0.8818
Aprire:
$0.88
Volume 24 ore:
26,317
Relative Volume:
0.25
Capitalizzazione di mercato:
$37.06M
Reddito:
-
Utile/perdita netta:
$-31.37M
Rapporto P/E:
-0.6134
EPS:
-1.438
Flusso di cassa netto:
$-4.23M
1 W Prestazione:
-4.13%
1M Prestazione:
-12.67%
6M Prestazione:
-34.18%
1 anno Prestazione:
-49.02%
Intervallo 1D:
$0.8698
$0.9498
Intervallo di 1 settimana:
$0.8301
$0.95
Portata 52W:
$0.8301
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Nome
Mira Pharmaceuticals Inc
Settore
Industria
Telefono
813-369-5150
Indirizzo
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.882 | 37.06M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,197.53 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.95 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.91 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.76 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.11 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:-0.046 - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Pharmaceuticals (MIRA) Holds Near Support with Modest Gains, Resistance at $0.97 in FocusStock Surge Alerts - dars.gov.et
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan
MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Pharmaceuticals Company Profile & Introduction - Moomoo
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et
What's going on with MIRA Pharma stock Tuesday? - MSN
MIRAMira Pharmaceuticals Inc Options - Finviz
MIRA Q3 2025 Earnings: Loss Narrows as EPS Surprises to the Upside, but Stock SlipsEarnings Revision Upgrade - dars.gov.et
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo
MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell Microcap Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com
MIRA Pharmaceuticals Inc. (MIRA) Rallies 11%: Approaching Key Resistance LevelEquity Put Call - dars.gov.et
Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView
K6S Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Forecast — Price Target — Prediction for 2027 - TradingView
Mira Pharmaceuticals Inc Azioni (MIRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):